Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | ARAF | P10398 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | HCK | P08631 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9967498 | 0.94 | MAPK14 (0.44) | BRAFLCKKDRMAPK14RAF1 | |
| SCHEMBL3590773 | 0.92 | BRAF (0.47) | BRAFLCKKDRMAPK14RAF1 | |
| SCHEMBL9967522 | 0.91 | BRAF (0.48) | BRAFLCKKDRMAPK14RAF1 | |
| SCHEMBL3584687 | 0.89 | BRAF (0.48) | BRAFLCKKDRRAF1 | |
| SCHEMBL3588296 | 0.89 | MAPK14 (0.45) | BRAFLCKKDRMAPK14LYN | |
| SCHEMBL3578558 | 0.87 | BRAF (0.41) | BRAFMAPK14MAPT | |
| SCHEMBL9970883 | 0.87 | MAPK14 (0.42) | BRAFLCKKDRMAPK14RAF1 | |
| SCHEMBL3593212 | 0.86 | LCK (0.48) | BRAFLCKKDRRAF1LYN | |
| SCHEMBL3594934 | 0.86 | LMNA (0.48) | BRAFMAPK14RAF1 | |
| SCHEMBL3583138 | 0.85 | EPHB2 (0.41) | BRAFLCKKDRMAPK14LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662147-B2 | Phenylhydrazine/anhydride adducts and anaerobic curable compositions using same | Henkel IP & Holding GmbH (DE) | 2020-05-26 | — | — | US | claimed |
| EP-3209640-B1 | PHENYLHYDRAZINE/ANHYDRIDE ADDUCTS AND ANAEROBIC CURABLE COMPOSITIONS USING SAME | Henkel IP & Holding GmbH (DE) | 2019-07-10 | — | — | EP | claimed |
| EP-3209702-B1 | ANAEROBIC CURABLE COMPOSITIONS HAVING NOVOLAC VINYL ESTERS | Henkel IP & Holding GmbH (DE) | 2018-12-12 | — | — | EP | claimed |
| US-9957344-B2 | Anaerobic curable compositions having novolac vinyl esters | Henkel IP & Holding GmbH (DE) | 2018-05-01 | — | — | US | claimed |
| EP-3209702-A1 | ANAEROBIC CURABLE COMPOSITIONS HAVING NOVOLAC VINYL ESTERS | Henkel IP & Holding GmbH (DE) | 2017-08-30 | — | — | EP | claimed |
| EP-3209640-A1 | PHENYLHYDRAZINE/ANHYDRIDE ADDUCTS AND ANAEROBIC CURABLE COMPOSITIONS USING SAME | Henkel IP & Holding GmbH (DE) | 2017-08-30 | — | — | EP | claimed |
| US-20170226256-A1 | ANAEROBIC CURABLE COMPOSITIONS HAVING NOVOLAC VINYL ESTERS | HENKEL AG & CO. KGAA (DE) | 2017-08-10 | — | — | US | claimed |
| US-20170217879-A1 | PHENYLHYDRAZINE/ANHYDRIDE ADDUCTS AND ANAEROBIC CURABLE COMPOSITIONS USING SAME | HENKEL AG & CO. KGAA (DE) | 2017-08-03 | — | — | US | claimed |
| US-8598279-B2 | Adducts useful as cure components for anaerobic curable compositions | Henkel IP US LLC (US) | 2013-12-03 | — | — | US | claimed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | claimed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | claimed |
| EP-1927607-B1 | Two-part polyurethane/vinyl ester hybrid foam system and its use as flame-retardant material and material for pour-and-set foam in openings in buildings | HILTI AG (LI) | 2009-12-23 | — | — | EP | claimed |
| EP-1927609-B1 | Multi-part polyurethane/vinyl ester hybrid foam system and its use | HILTI AG (LI) | 2009-11-04 | — | — | EP | claimed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | claimed |
| US-20090025874-A1 | Novel Adducts Useful As Cure Components For Anaerobic Curable Compositions | HENKEL CORPORATION (US) | 2009-01-29 | — | — | US | claimed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | claimed |
| US-6835762-B1 | Cure accelerators for anaerobic curable compositions | HENKEL CORPORATION | 2004-12-28 | — | — | US | claimed |
| EP-3827062-B1 | ANAEROBICALLY CURABLE COMPOSITIONS COMPRISING A METALLOCENE AND ACETYL PHENYL HYDRAZINE CURING SYSTEM | HENKEL AG & CO KGAA (DE) | 2024-05-22 | — | — | EP | disclosed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | FYN, ABL2, LCK | BRAF 11/4885LCK 3/4885KDR 13/4885 |
| US-10662147-B2 | Phenylhydrazine/anhydride adducts and anaerobic curable compositions using same | AHCY, BAP1, GLO1 | BRAF 2711/4885LCK 4867/4885KDR 4268/4885 |
| US-20170217879-A1 | PHENYLHYDRAZINE/ANHYDRIDE ADDUCTS AND ANAEROBIC CURABLE COMPOSITIONS USING SAME | AHCY, BAP1, GLO1 | BRAF 2711/4885LCK 4867/4885KDR 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.